相似文献
1
Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates.
Infect Immun. 1996 Jul;64(7):2824-8. doi: 10.1128/iai.64.7.2824-2828.1996.
2
Isolation and characterization of Pseudomonas pseudomallei flagellin proteins.
Infect Immun. 1994 May;62(5):1914-9. doi: 10.1128/iai.62.5.1914-1919.1994.
3
Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders.
Front Cell Infect Microbiol. 2012 Aug 15;2:108. doi: 10.3389/fcimb.2012.00108. eCollection 2012.
4
Protection against experimental melioidosis following immunisation with a lipopolysaccharide-protein conjugate.
J Immunol Res. 2014;2014:392170. doi: 10.1155/2014/392170. Epub 2014 May 7.
5
Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates.
PLoS One. 2013 May 31;8(5):e64680. doi: 10.1371/journal.pone.0064680. Print 2013.
6
Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis.
Infect Immun. 2014 Aug;82(8):3206-13. doi: 10.1128/IAI.01847-14. Epub 2014 May 27.
7
Rapid DNA vaccination against Burkholderia pseudomallei flagellin by tattoo or intranasal application.
Virulence. 2017 Nov 17;8(8):1683-1694. doi: 10.1080/21505594.2017.1307485. Epub 2017 Apr 19.
8
Antilipopolysaccharide II: an antibody protective against fatal melioidosis.
Clin Infect Dis. 1999 Oct;29(4):813-8. doi: 10.1086/520441.
9
Sequence- and Structure-Based Immunoreactive Epitope Discovery for Burkholderia pseudomallei Flagellin.
PLoS Negl Trop Dis. 2015 Jul 29;9(7):e0003917. doi: 10.1371/journal.pntd.0003917. eCollection 2015.
10
Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei.
Clin Vaccine Immunol. 2017 Nov 6;24(11). doi: 10.1128/CVI.00206-17. Print 2017 Nov.
引用本文的文献
1
Melioidosis vaccines: recent advances and future directions.
Front Immunol. 2025 Jun 24;16:1582113. doi: 10.3389/fimmu.2025.1582113. eCollection 2025.
2
Complex Subunit and Glycoconjugate Vaccines and Their Potential to Elicit Cross-Protection to Complex.
Vaccines (Basel). 2024 Mar 15;12(3):313. doi: 10.3390/vaccines12030313.
3
Melioidosis Patient Survival Correlates With Strong IFN-γ Secreting T Cell Responses Against Hcp1 and TssM.
Front Immunol. 2021 Jul 30;12:698303. doi: 10.3389/fimmu.2021.698303. eCollection 2021.
4
Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia ΔtonB Δhcp1 live attenuated vaccines.
NPJ Vaccines. 2021 May 13;6(1):72. doi: 10.1038/s41541-021-00333-4.
5
Recent advances on smart glycoconjugate vaccines in infections and cancer.
FEBS J. 2022 Jul;289(14):4251-4303. doi: 10.1111/febs.15909. Epub 2021 Jun 1.
6
An Evolutionary Arms Race Between and Host Immune System: What Do We Know?
Front Microbiol. 2021 Jan 21;11:612568. doi: 10.3389/fmicb.2020.612568. eCollection 2020.
7
Novel multi-component vaccine approaches for Burkholderia pseudomallei.
Clin Exp Immunol. 2019 May;196(2):178-188. doi: 10.1111/cei.13286. Epub 2019 Apr 8.
8
Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa.
PLoS One. 2018 Sep 6;13(9):e0203143. doi: 10.1371/journal.pone.0203143. eCollection 2018.
9
Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.
Adv Biochem Eng Biotechnol. 2021;175:355-378. doi: 10.1007/10_2018_71.
10
Immune response to recombinant Burkholderia pseudomallei FliC.
PLoS One. 2018 Jun 14;13(6):e0198906. doi: 10.1371/journal.pone.0198906. eCollection 2018.
本文引用的文献
1
India: is it plague?
Lancet. 1994 Nov 12;344(8933):1359.
2
Interaction of insulin with Pseudomonas pseudomallei.
Infect Immun. 1993 Oct;61(10):4045-50. doi: 10.1128/iai.61.10.4045-4050.1993.
3
Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei.
Infect Immun. 1995 Sep;63(9):3348-52. doi: 10.1128/iai.63.9.3348-3352.1995.
4
Isolation and characterization of Pseudomonas pseudomallei flagellin proteins.
Infect Immun. 1994 May;62(5):1914-9. doi: 10.1128/iai.62.5.1914-1919.1994.
5
Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.
J Immunol. 1981 Sep;127(3):1011-8.
6
Studies on the immunogenicity and tolerogenicity of T-independent antigens.
J Immunol. 1983 Nov;131(5):2196-203.
7
Release of ethanolamine pyrophosphate during mild acid hydrolysis of the lipopolysaccharide of Pseudomonas aeruginosa.
Eur J Biochem. 1971 Aug 16;21(3):400-3. doi: 10.1111/j.1432-1033.1971.tb01483.x.
8
9
Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
J Infect Dis. 1986 Oct;154(4):682-8. doi: 10.1093/infdis/154.4.682.
10
Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand.
J Infect Dis. 1989 May;159(5):890-9. doi: 10.1093/infdis/159.5.890.
Zotero 插件